JP2024510098A5 - - Google Patents
Info
- Publication number
- JP2024510098A5 JP2024510098A5 JP2023550109A JP2023550109A JP2024510098A5 JP 2024510098 A5 JP2024510098 A5 JP 2024510098A5 JP 2023550109 A JP2023550109 A JP 2023550109A JP 2023550109 A JP2023550109 A JP 2023550109A JP 2024510098 A5 JP2024510098 A5 JP 2024510098A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- polypeptide chain
- seq
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189359.8 | 2021-02-19 | ||
| CN202110189359 | 2021-02-19 | ||
| PCT/CN2022/076832 WO2022174813A1 (zh) | 2021-02-19 | 2022-02-18 | 抗GPRC5DxBCMAxCD3三特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510098A JP2024510098A (ja) | 2024-03-06 |
| JP2024510098A5 true JP2024510098A5 (https=) | 2025-02-28 |
Family
ID=82932102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550109A Pending JP2024510098A (ja) | 2021-02-19 | 2022-02-18 | 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250074996A1 (https=) |
| EP (1) | EP4296286A4 (https=) |
| JP (1) | JP2024510098A (https=) |
| CN (1) | CN116897166A (https=) |
| AU (1) | AU2022223152B2 (https=) |
| CA (1) | CA3211407A1 (https=) |
| TW (1) | TWI830151B (https=) |
| WO (1) | WO2022174813A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023543826A (ja) * | 2020-09-29 | 2023-10-18 | イノベント バイオロジクス（シンガポール）プライベート リミティド | 抗ｃｄ３抗体およびその使用 |
| IL317463A (en) * | 2022-06-06 | 2025-02-01 | Shandong Simcere Biopharmaceutical Co Ltd | Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application |
| US20260078195A1 (en) * | 2022-09-09 | 2026-03-19 | Beijing Mabworks Biotech Co., Ltd | Multi-specific antibody binding to bcma, gprc5d and cd3, and use thereof |
| CN117924485A (zh) * | 2022-10-25 | 2024-04-26 | 上海祥耀生物科技有限责任公司 | 一种抗gprc5d的多特异性抗体 |
| TW202434644A (zh) | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| TW202502826A (zh) | 2023-06-06 | 2025-01-16 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｇｐｒｃ５ｄ／ｂｃｍａ／ｃｄ３三特異性抗體的製備及其用途 |
| WO2025056013A1 (zh) * | 2023-09-13 | 2025-03-20 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合gprc5d和cd3的双特异性抗体的药物组合物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025092742A1 (zh) * | 2023-10-30 | 2025-05-08 | 美国礼至生物医药股份有限公司 | 结合bcma的抗体以及包含其的多特异性抗体 |
| WO2025119153A1 (zh) * | 2023-12-04 | 2025-06-12 | 山东先声生物制药有限公司 | 一种多特异性抗体的组合物及其制备方法和应用 |
| WO2025134050A1 (en) * | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025134049A1 (en) * | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025131075A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3和抗cd3多特异性抗体及用途 |
| CN117843788B (zh) * | 2024-01-09 | 2025-02-11 | 四川大学 | 一种抗gprc5d的抗体及其多特异性抗体和相关应用 |
| WO2025190400A1 (zh) * | 2024-03-15 | 2025-09-18 | 福佑泰生物制药公司 | 抗dll3抗体及其用途 |
| WO2025194478A1 (en) * | 2024-03-22 | 2025-09-25 | Biofront Ltd | Antibodies binding to cd3 and gprc5d, and uses thereof |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| PE20120540A1 (es) * | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US9708412B2 (en) * | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US10894823B2 (en) * | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| EP3645050A4 (en) * | 2017-06-25 | 2021-08-11 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| TWI829667B (zh) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| UA130542C2 (uk) * | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| CN113811546B (zh) * | 2019-05-07 | 2025-03-11 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| CN112062851B (zh) * | 2019-06-11 | 2022-09-09 | 南京驯鹿医疗技术有限公司 | 靶向bcma嵌合抗原受体的抗体及其应用 |
-
2022
- 2022-02-18 US US18/546,862 patent/US20250074996A1/en active Pending
- 2022-02-18 CN CN202280015788.6A patent/CN116897166A/zh active Pending
- 2022-02-18 CA CA3211407A patent/CA3211407A1/en active Pending
- 2022-02-18 EP EP22755586.9A patent/EP4296286A4/en active Pending
- 2022-02-18 WO PCT/CN2022/076832 patent/WO2022174813A1/zh not_active Ceased
- 2022-02-18 TW TW111106048A patent/TWI830151B/zh active
- 2022-02-18 AU AU2022223152A patent/AU2022223152B2/en active Active
- 2022-02-18 JP JP2023550109A patent/JP2024510098A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024510098A5 (https=) | ||
| JP2022061992A5 (https=) | ||
| JP2024175003A5 (https=) | ||
| CN102906113B (zh) | 治疗性dll4结合蛋白 | |
| JP2024522360A5 (https=) | ||
| JP2023509448A5 (https=) | ||
| JP2021524478A5 (https=) | ||
| JP2023538945A5 (https=) | ||
| JP2022507487A5 (https=) | ||
| JP2018108081A5 (https=) | ||
| RU2009107494A (ru) | АНТИТЕЛА К ErbB2 | |
| JP2023503846A5 (https=) | ||
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| JP2019513018A5 (https=) | ||
| RU2012112340A (ru) | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| CN107530420A (zh) | 抗tim‑3抗体 | |
| JP2021533159A5 (https=) | ||
| JP2025067915A5 (https=) | ||
| JP2020515277A5 (https=) | ||
| JP2012532851A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2023506834A5 (https=) | ||
| JP2020502233A5 (https=) |